Online inquiry

IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ374MR)

This product GTTS-WQ374MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TYRP1 gene. The antibody can be applied in Malignant melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000550.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7306
UniProt ID P17643
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ374MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12295MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ10317MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ6875MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ3451MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ1739MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ3039MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ3115MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ6357MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW